Abstract:Aim: Prescription drug prices in the United States are considered rather extreme. Americans spend over $460 billion on drugs annually, or almost 17 percent of total national healthcare spending. How innovation incentives and insurance coverage drive pricing, diffusion, and utilization of drugs, under conditions of risk and competition, are multi-dimensional issues in medical economics that remain under-explored in the current empirical literature. We seek to address these issues in reviewing relevant studies presented at the 2020 AEA-ASSA annual convention. Approach: Drawn from the 2020 convention panel sessions devoted to health economics, empirical evidence was thematically analyzed for charted new research terrains and trajectories. Their theoretical and practical implications on efficiency, effectiveness, and value in drug production and consumption were then identified. Findings: With certain qualifications, evidence confirms price inelasticity of prescription drugs and medical treatments, along with substitution effects from high or continuously rising prices. While health insurance induces ex ante moral hazard, albeit on a larger scale than previously considered, losing dependent coverage can incentivize price-substitution to risky and illegal drugs, including those sold on the black market. At the firm level, drug patenting and exclusivity rights suggest that innovation incentives increase new or novel clinical trials and generic utilization to a considerable extent. But innovation can produce strong, offsetting effects. It can distort competition and cause (at times sharp) price increases from product-hopping, (compensatory) list pricing, industry mergers and acquisitions, and capture of positive spillovers by competitors, rather than by focal developers, in follow-on innovations. In fine, there remains room for opportunism among firms, particularly market incumbents, and many loopholes are unplugged by U.S. healthcare reform. These make drug utilization costly to the insured, and risky to those who are - or become - uninsured or underinsured for various reasons. Conclusions: The fundamental disconnect between innovation cost and drug pricing demands public attention and policy intervention, which have proved largely elusive to date. Gaming the system in the name of scientific invention and discovery to reap additional benefits, at the expense of consumer health and income, brings to question the offsetting benefits of firm innovation. It also raises separate issues of fairness and equity. Innovation needs to be considered from the perspective of value lines and beyond conventional marketing incentives to drug utilization, with or without insurance coverage. Cost-effectiveness and cost-benefit analyses figure prominently under a value-based system of resource allocation, insurance, medical prescription, purchasing, and reimbursement.

Financial Conflicts of Interest and Reporting Bias Regarding the Association between Sugar-Sweetened Beverages and Weight Gain: A Systematic Review of Systematic Reviews

Cost-Related Non-Adherence to Prescribed Medicines: What Are Physicians' Moral Duties?

[Double-blind comparative study on the effects of lofepramine and amitriptyline in depressive outpatients (author's transl)].

Widening consumer access to medicines: a comparison of prescription to non-prescription medicine switch in Australia and New Zealand

"Too much medicine": Insights and explanations from economic theory and research

Socioeconomic factors, medication subsidisation and the use of preventative cardiovascular disease medications in Australia.

Determinants of attitude and intention towards private health insurance: a comparison of insured and uninsured young adults in Australia

Progressivity of out-of-pocket costs under Australia's universal health care system: A national linked data study

Australian Pharmaceutical Policy: Price Control, Equity, and Drug Innovation in Australia

Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics

[Toxoplasmosis of poikilothermal vertebrates; unity or plurality of Toxoplasma species].

Impaired quality of life of healthy young smokers.

Strategies to Help Patients Navigate High Prescription Drug Costs

Pricing, profits and pharmacoeconomics--for whose benefit?

P211 PRESCRIPTION AND DISPENSING DURATION OF MEDICINES FOR CHRONIC CONDITIONS: A REVIEW OF INTERNATIONAL POLICIES AND EVIDENCE TO INFORM THE AUSTRALIAN SETTING

Perceptions with Type 2 Diabetes Mellitus of the Value of Prescribed Medications Among Malaysian Adults: A Qualitative Study

Prescription charge policy acceptance among UK adults with and without long-term health conditions: a mixed-method survey

Direct-to-consumer advertising of prescription medication in New Zealand

Takayasu's arteritis mimicking aortic intramural hematoma in a female patient with chest pain.

"You've got to breathe, you know" - asthma patients and carers' perceptions around purchase and use of asthma preventer medicines